Management Teamabout : management team
 Dr. Aladar A. Szalay, who formed Genelux Corporation in 2001, is internationally recognized as a leader in the monitoring of gene regulation and in whole cell and live organism imaging using light-emitting proteins or protein fusions. Based on his long-time research interest and recent discoveries, the company is utilizing live microorganisms to locate (diagnose) and eliminate (therapy) human tumor xenografts. In addition, to guide the research and development program of Genelux Corporation, Dr. Szalay currently holds a university professor position at the Rudolf Virchow Center of Experimental Biomedicine, School of Medicine, and also at the Biocenter at the University of Würzburg in Würzburg, Germany, where he directs a research program with graduate students and post-doctoral fellows on whole body imaging. . He was recently appointed to a full professor position in the Department of Radiation Oncology at the Rebecca and John Moores Comprehensive Cancer Center, at the University of California, San Diego. His previous academic appointments were: Professor of molecular genetics and microbiology and founding Director of the Center for Molecular Biology and Gene Therapy at Loma Linda University School of Medicine in Loma Linda, California; Canadian Pacific Endowed Chair Professor of biotechnology and molecular genetics at the University of Alberta in Edmonton, Canada; Associate Research Scientist of molecular genetics at the Boyce Thompson Institute and adjunct professor at Cornell University in Ithaca, New York; and Gosney fellow at the California Institute of Technology in Pasadena, California. He has published over 160 scientific papers and holds over 50 issued patents and patent applications. Dr. Szalay is the recipient of the Wilhelm Exner Award (Medal for Excellence in Science) from Austria and the Alexander von Humboldt Prize from Germany, among others. He has functioned as an advisor for numerous research foundations, served on the Board of Directors and the Scientific Advisory Board for several biomedical start-up companies and was invited to serve as a genetic engineering, gene transfer and therapy expert for several multi-national pharmaceutical and diagnostic equipment manufacturing companies in the US, Europe and Japan.
 Dr. Albert Röder joined Genelux Corporation in 2004 after retiring from Roche Applied Science as Head of Global R&D and Marketing Support. In February of that year, he was elected to the Board of Directors of Genelux Corporation. His distinguished 33-year career in the pharmaceutical and diagnostics industries included several operative and leadership positions in research and development, manufacturing, marketing, strategy and business development within international cross-functional teams. Before joining Roche, Dr. Röder worked for Boehringer Mannheim, where he rose to Head of Research in Enzymology, Proteinchemistry and Chemistry, then to Head of the Global Product Supply Unit of its Business Unit, Biochemicals. He holds a PhD in organic chemistry from the University of Tübingen in Germany.
A physician and medical researcher with more than 30 years of experience in clinical oncology product development, Dr. Paul Scigalla joined Genelux Corporation in September 2011 as the company’s Chief Medical Officer. He is responsible for providing strategic direction of the company’s Clinical Program to secure expeditious market approval for current and future investigational product candidates. A native of Germany, Paul Scigalla received his medical training at Humboldt University in Berlin, graduating in 1970. After a fellowship in pediatric nephrology, Dr. Scigalla specialized in anemia in children with end-stage renal failure, earning his Ph.D. for research in the regulatory mechanism of erythropoiesis in end-stage renal failure in 1982. After 14 years in academic clinical practice, principally spent at the Pediatric Clinic of the Free University in Berlin, Dr. Scigalla entered the pharmaceutical industry in 1984. As head of Clinical Research for nephrology, oncology and bone metabolism at Boehringer Mannheim GmbH, he was responsible for the preclinical and clinical development of erythropoietin (licensed from Genetics Institute). This compound received licensing approval in Europe in 1988, only six years following discovery of the protein. In 1992, Dr. Scigalla was appointed Professor of Medicine at the University of Heidelberg. He later served as Boehringer Mannheim’s Senior Vice President and head of Global Development Therapeutics. Amongst many projects, he coordinated the development of ibandronate, a bisphosphonates for the treatment of bone metastases. Since leaving Boehringer Mannheim in 1998, Dr. Scigalla served as Senior Vice President at SUGEN, Inc., responsible for the clinical development of multiple receptor tyrosine kinase inhibitors, including semaxanib (currently in late-stage clinical trials for the treatment of cancer) and as Vice President Research Oncology, Pfizer Bedminster, New Jersey. Since August 2003, he has served as a consultant to several pharmaceutical companies in US, Japan and Europe. Dr. Scigalla has published over 200 manuscripts in scientific journals and served as editor of 8 books focused on pediatric nephrology and erythropoiesis. Prof. Scigalla has major interests in the clinical development of novel biologically-targeted therapies.
 Dr. Staib holds a PhD in biochemistry and human genetics and a master's degree in biochemistry, microbiology and animal physiology from the University of Würzburg. Her PhD thesis was honored as the best in the University of Würzburg in 1998. In 2007 she completed her habilitation in Virology at the Medical Faculty of the Technical University of Munich in Germany. Dr. Staib joined Genelux Corporation in 2006. As head of product development, she manages process development and manufacturing, and the development of companion analytics for virus processing, quality control and for clinical trials. She is representing Genelux GmbH as Sponsor of the European clinical trials also collaborating with the Genelux scientific research team in San Diego preclinical product testing and with the clinical trials team for preparation of regulatory documents. Prior to joining Genelux Corporation, she was head of a research group at the Institute of Virology at the Technical University of Munich in Germany, where she gained eight years of experience carrying out leading research in the field of orthopox and vaccinia viruses, with an emphasis on vaccine development and optimization. Dr. Staib has co-authored a variety of original peer-reviewed scientific publications, as well as reviews, book chapters and patent applications.
 Dr. Yu was an integral part of the initial scientific research that led to the formation of Genelux Corporation and was the Company's first employee. He received a PhD in anatomy and biochemistry in 2002 from Loma Linda University and a BA from the University of Utah in 1995 after moving to the U.S. from his native China. After several years at the center of Preclinical research and development at Genelux, Dr. Yu now leads the Company's Clinical Operations group, managing protocol development and overseeing all aspects of our human Clinical Trial program.
 Dr. Ronald Roy A. Simus joined Genelux Corporation as the Company's first investor in 2002 when the Company was first attempting to build its initial scientific discoveries into a biomedical research and development company. Since this time, Dr. Simus has been involved with the growth and evolution of the Company, including participating in the Company's management, corporate strategy, fundraising and operations. Today, he serves as the Company's Interim Secretary, its Vice President of Investor Relations and Investments and is also a member of the Company's Board of Directors. Dr. Simus holds a DDS and an MS in orthodontics and dentofacial orthopedics from Loma Linda University.
Copyright © 2011 Genelux |
Disclaimer
|